Welcome back to Health Unlocked! In this episode, Jasen Petersen takes us deep into the world of medical devices, regulatory pathways, and the bold vision for the IBAL platform. Jasen Petersen breaks down the crucial differences between drugs and devices; why it matters for innovation, safety, and getting new therapies to patients faster.
You'll hear firsthand about IBAL’s journey through regulatory approval in Mexico and the UAE, how previous groundwork helps set the stage for U.S. expansion, and the strategic thinking behind choosing the right device pathway. Jasen also tackles the complexities of claims, regulations, and evidence, explaining why language, transparency, and governance are make-or-break factors. He explores how new funding and governance models like Decentralized Science (DeSci) and DAOs can unlock ingenuity and integrity, helping promising therapies break out of the traditional pharma mold.
If you’re curious about the future of medical innovation, how “terrain-aligned” approaches challenge the status quo, or just want an inside look at the regulatory chess game behind breakthrough products, this is an episode you don’t want to miss!
Timestamps:
00:00 Drug Development vs. FDA Standards
04:45 "Medical Device Approval Simplified"
08:43 FDA Evaluation and Approval Process
12:25 "Why Supplements Aren't Regulated Drugs"
13:38 Pharma Challenges: Funding, Claims, Safety
19:16 "IBAL's Potential Across Indications"
23:07 Transparent Governance Ensures Accountability
24:02 "Mission-Driven Decision Making"
29:15 "Ion Gel Healing and Data"
31:36 "Paradigm Shifts and Awareness"
33:30 "Ion Gel: Transparent Evidence"
Device Pathways, Regulatory Approvals, and the Future of IBAL: Insights from the “Health Unlock” Podcast
In the latest episode of the “Health Unlock the Power of Salutogenesis” podcast, host Jasen Petersen dives deep into the world of medical devices, regulatory strategies, and the innovative journey of IBAL, a platform poised to transform infection control and wound healing. This episode unpacks what sets drugs apart from devices and explores how governance models like DeSci and DAO are driving both transparency and speed in healthcare innovation.
Understanding the Drug vs Device Distinction
A common misconception is that the FDA’s regulatory approach is solely designed for drugs. Jasen Petersen addresses this by distinguishing drugs from devices based on their primary mode of action. Drugs achieve their purpose through pharmacologic, metabolic, or immunologic actions such as receptor binding or pathway inhibition. This approach requires comprehensive clinical testing to determine dosage, interactions, and long-term safety.
IBAL, according to Jasen Petersen, takes an entirely different approach. Rather than manipulating biological processes, it supplies localized essential metal cofactors to restore cell inputs, promoting healing without forcing biology to comply with a single target mechanism. This difference is crucial since it shifts IBAL’s developmental strategy from the lengthy and costly process required for drugs to a layered, platform-based approach typical for medical devices.
Exploring Device Regulatory Pathways: 510k, De Novo, and PMA
The podcast outlines the three major regulatory lanes for medical devices: 510k, de novo, and PMA.
510k (Substantial Equivalence): This pathway allows for devices to be approved if they’re similar to already cleared devices. Here, the FDA examines the claims and the evidence supporting them, not necessarily everything the device can do. This strategy proves beneficial for iBAL, which matches the mode of action of other approved infection control and wound healing devices.
De Novo: Designed for novel devices that pose low to moderate risk, the de novo pathway enables innovations that don’t fit neatly into the substantial equivalence category but still maintain a strong safety profile.
Premarket Approval (PMA): Reserved for high-risk devices, PMA involves the strictest evidence requirements and is akin to the drug approval process.
The episode emphasizes that, for IBAL’s first product, the ion gel, cleared for infection control and wound healing, the 510k pathway is the fastest and most cost-effective route in the United States.
International Approvals and Their Impact
IBAL’s journey has already included successful navigation of regulatory agencies in Mexico and UAE, with its ion gel currently in real-world use in both markets. This international approval provides credibility, real-world data, and manufacturing experience, all of which strengthen the platform’s case as it approaches FDA approval in the U.S. Jasen Petersen notes that while U.S. regulators may seek additional demographic-specific data, the breadth of IBAL’s clinical evidence puts it ahead of many competitors.
Pitfalls and Failure Modes in Regulatory Strategy
According to Jasen Petersen, the greatest risk for regulatory failure is not technical or scientific but linguistic. Misframing the product with drug-related terminology could lead to its evaluation as a drug, thereby increasing the development timeline and costs. Overclaiming or lack of robust quality systems can also expand the evidence burden or halt progress entirely. Staying disciplined in claims and transparent in evidence is key to IBAL’s continued success.
How DeSci and DAO Revolutionize Funding and Governance
The episode reveals how governance models like DeSci and DAO unlock a new paradigm in funding and decision-making. Unlike traditional venture capital, which ties decision-making closely to ROI and can incentivize data manipulation, DAO offers governance and transparency without direct financial returns. This enables decisions focused on mission and broader access, not solely profit margins. Token holders in DAO guide project priorities, evidence plans, and milestones, ensuring integrity at every step.
What Does This Unlock for Healthcare?
If IBAL’s approach succeeds, it offers more than a single miracle product; it introduces a scalable, transparent, and repeatable development pattern for terrain-aligned interventions. Instead of waiting years for a binary, high-stakes drug approval, IBAL’s device pathway allows for iterative expansion of use cases, quicker real-world impact, and the ability to add new indications as clinical evidence grows.
Conclusion and Future Perspective
Jasen Petersen highlights a paradigm shift in healthcare innovation. With established international approvals and a strong commitment to transparency and governance, IBAL is set to redefine how medical devices reach patients. As the process continues to gain traction, expect to see further data and insights on IBAL’s real-world impact in upcoming episodes. This new approach may soon be recognized as common sense; a testament to the evolving landscape of medical technology.
“Disclaimer: Informational only. Not medical advice. Consult your doctor for guidance.”
Show Website - https://powerofsalutogenesis.com/
Ionic Alliance Foundation Website - https://iaf.care/
Jasen Petersen's LinkedIn - https://www.linkedin.com/in/jasenepetersen/
TopHealth Media Website - https://tophealth.care/